We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Fundamental aspects
-
1. Inflammation and tissue homeostasis
- Prof. Herman Waldmann
-
2. Introduction to the immune system
- Prof. Herman Waldmann
-
3. Hematopoiesis: the making of an immune system
- Prof. Paul J. Fairchild
-
4. Inflammation: purposes, mechanisms and development
- Prof. Pietro Ghezzi
-
5. Phagocytosis
- Dr. Eileen Uribe-Querol
-
6. Regulated cell death mechanisms and their crosstalk with the immune system 1
- Dr. Luis Alberto Baena-Lopez
-
7. Regulated cell death mechanisms and their crosstalk with the immune system 2
- Dr. Luis Alberto Baena-Lopez
- Innate immunity
-
11. Cells of the innate immune system
- Prof. Kevin Maloy
-
12. Microbial recognition and the immune response
- Dr. Dana Philpott
-
13. Toll-like receptor signalling during infection and inflammation
- Prof. Luke O'Neill
- Intercellular mediators
-
14. Chemokines
- Dr. James E. Pease
-
15. Cytokines
- Prof. Iain McInnes
-
16. IL-1 family cytokines as the canonical DAMPs of the immune system
- Prof. Seamus Martin
-
17. Glycans at the frontiers of inflammation, autoimmunity and cancer
- Prof. Salomé S. Pinho
-
18. Glycoimmunology
- Prof. Paula Videira
- Adaptive immunity B cells
-
21. Antigen recognition in the immune system
- Prof. Herman Waldmann
-
22. B cell biology
- Prof. Richard Cornall
-
23. Antibody structure and function: antibody structure
- Dr. Mike Clark
-
24. Antibody structure and function: antibody function
- Dr. Mike Clark
-
25. Antibody genes and diversity
- Dr. Mike Clark
-
26. In vivo antibody discovery and hybridoma technology
- Prof. Dr. Katja Hanack
-
27. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
29. The immunobiology of Fc receptors
- Prof. Mark Cragg
-
30. Immunoreceptors
- Prof. Anton van der Merwe
-
31. Affinity, avidity and kinetics in immune recognition
- Prof. Anton van der Merwe
- Adaptive immunity T cells
-
32. The thymus and T cell development: a primer
- Prof. Georg Holländer
-
33. Lineage decisions in the thymus: T cell lineage commitment
- Prof. Bruno Silva-Santos
-
34. Lineage decisions in the thymus: αβ and γδ T cell lineages
- Prof. Bruno Silva-Santos
-
35. CD4 T cell subsets
- Dr. Brigitta Stockinger
-
36. Cytotoxic T lymphocytes
- Prof. Gillian M. Griffiths
-
37. Gamma delta T-cells
- Prof. Bruno Silva-Santos
-
38. Tfh and Tfr cells
- Prof. Luis Graca
-
39. Tissue resident memory T cells (TRM)
- Dr. Marc Veldhoen
-
40. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
- The importance of the MHC in immunity
-
41. The MHC and MHC molecules 1
- Prof. Jim Kaufman
-
42. The MHC and MHC molecules 2
- Prof. Jim Kaufman
-
43. Natural killer cells
- Dr. Philippa Kennedy
-
44. Human NK cells
- Prof. Lorenzo Moretta
-
46. NK cells in viral immunity
- Prof. Lewis Lanier
- Lymphocyte activation
-
47. Signal transduction by leukocyte receptors
- Dr. Omer Dushek
-
48. Immunological memory 1
- Prof. David Gray
-
49. Immunological memory 2
- Prof. David Gray
-
50. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
- Major cellular partners in immunity
-
51. The mononuclear phagocyte system - tissue resident macrophages: distribution and functions
- Prof. Emeritus Siamon Gordon
-
52. The mononuclear phagocyte system: tissue resident macrophages - activation and regulation
- Prof. Emeritus Siamon Gordon
-
53. Dendritic cells: professional antigen presenting cells
- Prof. Paul J. Fairchild
-
54. Mucosal immunology
- Prof. Daniel Mucida
- Immunological tolerance and regulation
-
55. Self-tolerance
- Prof. Herman Waldmann
-
56. Tolerance and autoimmunity
- Prof. Emerita Anne Cooke
-
57. The balance between intestinal immune homeostasis and inflammation
- Prof. Dr. Janneke Samsom
- Translational immunology - immune deficiency
-
58. Primary immunodeficiency disorders
- Dr. Smita Y. Patel
-
59. Changes in innate and adaptive immunity during human ageing 1
- Dr. Roel De Maeyer
-
60. Changes in innate and adaptive immunity during human ageing 2
- Dr. Roel De Maeyer
-
61. The aging immune system
- Prof. Ana Caetano
- Translational immunology - protection against pathogenic microbes
-
62. Immune responses to viruses
- Prof. Paul Klenerman
-
63. HIV and the immune system
- Prof. Quentin Sattentau
-
64. COVID-19: the anti-viral immune response
- Prof. Danny Altmann
-
65. Bacterial immune evasion
- Prof. Christoph Tang
-
66. The immunology underlying tuberculosis
- Prof. Thomas R. Hawn
-
67. Innate immunity to fungi
- Prof. Gordon D. Brown
-
68. Parasite immunity: introduction and Plasmodium
- Dr. Catarina Gadelha
-
69. Parasite immunity: Leishmania and Schistosoma
- Dr. Catarina Gadelha
-
70. Vaccination
- Dr. Anita Milicic
-
71. The history of vaccines 1
- Prof. Emeritus Anthony R. Rees
-
72. The history of vaccines 2
- Prof. Emeritus Anthony R. Rees
-
73. The history of vaccines 3
- Prof. Emeritus Anthony R. Rees
-
74. The science of vaccine adjuvants
- Dr. Derek O'Hagan
- Translational immunology - hypersensitivity, autoimmune disease and their management
-
75. Hypersensitivity diseases: type 1 hypersensitivity
- Prof. Herman Waldmann
-
76. Innate lymphoid cells in allergy
- Prof. Emeritus Shigeo Koyasu
-
77. Hypersensitivity diseases: type II-IV hypersensitivity
- Prof. Sara Marshall
-
78. Immune memory underlying lifelong peanut allergy
- Dr. Kelly Bruton
-
79. Memory B cells in allergy: B cell activation and response
- Dr. Kelly Bruton
-
80. Memory B cells in allergy: ontogeny, phenotype and plasticity
- Dr. Kelly Bruton
-
81. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
82. Interleukin-17: from clone to clinic
- Prof. Leonie Taams
-
83. Autoimmunity and type 1 diabetes
- Prof. Emerita Anne Cooke
-
84. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
85. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
86. Monoclonal antibodies in haemato-oncology
- Prof. Mark Cragg
-
87. Therapeutic antibodies
- Dr. Geoffrey Hale
-
88. Endothelial cells: regulators of autoimmune-neuroinflammation
- Dr. Laure Garnier
-
89. Neuroimmunometabolism
- Prof. Ana Domingos
-
90. The immunology of multiple sclerosis
- Dr. Joanne Jones
-
91. Immunology of the peripheral nervous system: the inflammatory neuropathies
- Dr. Simon Rinaldi
-
92. Ocular immunology: an overview of immune mechanisms operating in the eye
- Dr. Eleftherios Agorogiannis
-
93. Understanding myasthenia gravis and advances in its management
- Prof. Henry J. Kaminski
-
94. The immunology underlying rheumatic diseases
- Dr. Hussein Al-Mossawi
-
96. Complement and lupus
- Prof. Marina Botto
-
97. Immune mechanisms in liver diseases
- Prof. Paul Klenerman
- Translational immunology - transplantation immunology
-
98. Principles of transplantation: overview of the immune response
- Prof. Emerita Kathryn Wood
-
99. Factors influencing outcomes in clinical transplantation 1
- Prof. Emerita Kathryn Wood
-
100. Factors influencing outcomes in clinical transplantation 2
- Prof. Emerita Kathryn Wood
- Translational immunology - cancer immunology
-
101. Cancer immunology
- Prof. Tim Elliott
-
102. Cancer immunotherapy
- Prof. Tim Elliott
-
103. Myeloid-derived suppressor cells in cancer
- Prof. Dmitry Gabrilovich
-
104. IL-2 in the immunotherapy of autoimmunity and cancer
- Prof. Thomas Malek
-
105. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
Printable Handouts
Navigable Slide Index
- Introduction
- Overview of lecture: introduction
- Challenges of immune recognition
- Antigen recognition has unique features
- Overview of lecture: key binding concepts
- Affinity
- Kinetics
- Factors affecting affinity
- Affinity & kinetic constants for key immune interactions
- Avidity
- Multivalent high-avidity molecules
- Overview of lecture: measuring binding properties
- Methods for measuring binding properties
- Principles of surface plasmon resonance
- Measuring the affinity constant (1)
- Measuring the affinity constant (2)
- Scatchard plot
- Measuring affinity by SPR: an example
- Measuring the dissociation rate constant
- Measuring the association rate constant
- Example of measuring binding kinetics
- Measuring avidity
- Overview of lecture: cell surface molecules
- Cell surface molecule interactions are distinct
- Consequence of constraint to membranes
- Consequence of mechanical forces
- Consequence of cooperativity
- Cooperative binding example
- CD2/CD48 complex size affects TCR binding
- Conclusions
- Acknowledgments
Topics Covered
- Challenges of immune recognition
- Key binding concepts
- Affinity
- Kinetics
- Avidity
- Measuring binding properties
- Cell surface molecules
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
van der Merwe, A. (2020, November 30). Affinity, avidity and kinetics in immune recognition [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/YFIE6191.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Anton van der Merwe has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Biochemistry
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Anton Van der Merwe from the University of Oxford,
and I'm going to be talking about affinity,
avidity, and kinetics in immune recognition.
0:11
Here's an overview of my lecture.
After this introduction, I'll be talking about the key binding concepts,
discussing measuring binding properties,
and then finish by discussing the special features of cell surface molecules.
0:25
Now immune recognition is driven by protein-ligand interactions,
and the proteins and ligands can either be soluble or surface-associated.
A particular challenge for immune recognition is that the ligands e.g,
the antigens often arise from infectious organisms or cancer cells.
They are very diverse and can evolve rapidly.
To meet this challenge, the recognition proteins also
need to be very diverse and to be able to evolve rapidly.
Now the binding properties such as the affinity and kinetics of
immune protein-ligand interactions or what determines the functional outcome of binding.
Understanding these properties and how they measured
is important for understanding immune responses.
1:04
Antigen recognition involves hugely diverse, somatically generated,
and clonally expressed T and B cell antigen receptors,
also called TCR receptors and antibodies.
These develop on T and B cells during their development,
and this development includes
positive and negative selection events that depend
on the affinity of these receptors for self-antigen.
Now each TCR receptor on a maturity cell combine multiple similar ligands and
needs to able to discriminate between them based
on subtle differences in affinity and kinetics.
TCRs receptors and primary antibodies actually have quite low affinity for the ligand.
This isn't a problem for TCR receptors because TCR receptors and their ligands are
on cells and recognition that a cell-cell interface can tolerate low affinities.
It is a problem however for antibodies.
Primary antibodies compensate for the low-affinity
by increasing the valency of binding or the avidity,
and antibodies can undergo affinity maturation to
become high-affinity secondary antibodies.